BMY logo

Bristol-Myers Squibb (BMY) EBITDA

annual EBITDA:

$2.44B-$16.93B(-87.40%)
December 31, 2024

Summary

  • As of today (May 29, 2025), BMY annual EBITDA is $2.44 billion, with the most recent change of -$16.93 billion (-87.40%) on December 31, 2024.
  • During the last 3 years, BMY annual EBITDA has fallen by -$17.68 billion (-87.87%).
  • BMY annual EBITDA is now -87.87% below its all-time high of $20.12 billion, reached on December 31, 2021.

Performance

BMY EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherBMYincome statement metrics

quarterly EBITDA:

$4.48B+$1.93B(+75.50%)
March 31, 2025

Summary

  • As of today (May 29, 2025), BMY quarterly EBITDA is $4.48 billion, with the most recent change of +$1.93 billion (+75.50%) on March 31, 2025.
  • Over the past year, BMY quarterly EBITDA has increased by +$13.04 billion (+152.31%).
  • BMY quarterly EBITDA is now -19.35% below its all-time high of $5.55 billion, reached on March 31, 2021.

Performance

BMY quarterly EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherBMYincome statement metrics

TTM EBITDA:

$16.20B+$13.04B(+411.49%)
March 31, 2025

Summary

  • As of today (May 29, 2025), BMY TTM EBITDA is $16.20 billion, with the most recent change of +$13.04 billion (+411.49%) on March 31, 2025.
  • Over the past year, BMY TTM EBITDA has increased by +$10.88 billion (+204.59%).
  • BMY TTM EBITDA is now -19.46% below its all-time high of $20.12 billion, reached on December 31, 2021.

Performance

BMY TTM EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherBMYincome statement metrics

EBITDA Formula

EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization

BMY EBITDA Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year-87.4%+152.3%+204.6%
3 y3 years-87.9%-2.6%-15.4%
5 y5 years-66.9%+76.6%+110.0%

BMY EBITDA Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-87.9%at low-18.4%+152.3%-19.4%+411.5%
5 y5-year-87.9%at low-19.4%+152.3%-19.5%+411.5%
alltimeall time-87.9%+90.8%-19.4%+152.3%-19.5%+544.3%

BMY EBITDA History

DateAnnualQuarterlyTTM
Mar 2025
-
$4.48B(+75.5%)
$16.20B(+411.5%)
Dec 2024
$2.44B(-87.4%)
$2.55B(-46.6%)
$3.17B(-37.5%)
Sep 2024
-
$4.77B(+8.4%)
$5.07B(-1.5%)
Jun 2024
-
$4.40B(-151.4%)
$5.15B(-3.2%)
Mar 2024
-
-$8.56B(-292.2%)
$5.32B(-72.5%)
Dec 2023
$19.37B(+0.8%)
$4.45B(-8.2%)
$19.37B(-1.1%)
Sep 2023
-
$4.85B(+6.1%)
$19.59B(-1.2%)
Jun 2023
-
$4.57B(-16.7%)
$19.83B(-1.4%)
Mar 2023
-
$5.49B(+17.4%)
$20.11B(+4.6%)
Dec 2022
$19.22B(-4.5%)
$4.67B(-8.3%)
$19.22B(-0.4%)
Sep 2022
-
$5.10B(+5.0%)
$19.31B(-0.6%)
Jun 2022
-
$4.85B(+5.6%)
$19.42B(+1.4%)
Mar 2022
-
$4.60B(-3.4%)
$19.16B(-4.7%)
Dec 2021
$20.12B(+308.2%)
$4.76B(-8.7%)
$20.12B(+153.0%)
Sep 2021
-
$5.21B(+13.4%)
$7.95B(-0.6%)
Jun 2021
-
$4.59B(-17.2%)
$8.00B(+0.7%)
Mar 2021
-
$5.55B(-175.0%)
$7.95B(+61.2%)
Dec 2020
$4.93B(-33.2%)
-$7.41B(-240.9%)
$4.93B(-64.1%)
Sep 2020
-
$5.26B(+15.8%)
$13.72B(+34.6%)
Jun 2020
-
$4.54B(+79.2%)
$10.19B(+32.1%)
Mar 2020
-
$2.54B(+82.9%)
$7.72B(+4.6%)
Dec 2019
$7.38B(+8.7%)
$1.39B(-19.8%)
$7.38B(-4.4%)
Sep 2019
-
$1.73B(-16.4%)
$7.72B(-7.7%)
Jun 2019
-
$2.07B(-5.7%)
$8.36B(+19.2%)
Mar 2019
-
$2.19B(+27.2%)
$7.01B(+3.3%)
Dec 2018
$6.79B(+11.0%)
$1.73B(-27.4%)
$6.79B(+13.0%)
Sep 2018
-
$2.38B(+230.5%)
$6.01B(+18.9%)
Jun 2018
-
$719.00M(-63.5%)
$5.05B(-14.2%)
Mar 2018
-
$1.97B(+108.0%)
$5.89B(-3.7%)
Dec 2017
$6.12B(-5.4%)
$946.00M(-33.3%)
$6.12B(-4.7%)
Sep 2017
-
$1.42B(-8.9%)
$6.42B(-4.3%)
Jun 2017
-
$1.56B(-29.0%)
$6.71B(-2.7%)
Mar 2017
-
$2.19B(+75.7%)
$6.89B(+6.7%)
Dec 2016
$6.46B(+145.1%)
$1.25B(-26.8%)
$6.46B(+31.2%)
Sep 2016
-
$1.71B(-2.3%)
$4.92B(+13.2%)
Jun 2016
-
$1.75B(-0.9%)
$4.35B(+55.6%)
Mar 2016
-
$1.76B(-705.8%)
$2.80B(+6.1%)
Dec 2015
$2.64B(-13.6%)
-$291.00M(-125.7%)
$2.64B(-12.8%)
Sep 2015
-
$1.13B(+490.1%)
$3.02B(-1.2%)
Jun 2015
-
$192.00M(-88.0%)
$3.06B(-12.0%)
Mar 2015
-
$1.60B(+1569.8%)
$3.48B(+14.0%)
Dec 2014
$3.05B(-20.8%)
$96.00M(-91.8%)
$3.05B(-24.8%)
Sep 2014
-
$1.17B(+92.1%)
$4.06B(+3.2%)
Jun 2014
-
$609.00M(-48.2%)
$3.93B(-3.9%)
Mar 2014
-
$1.18B(+6.6%)
$4.09B(+6.2%)
Dec 2013
$3.85B(+20.3%)
$1.10B(+5.7%)
$3.85B(+9.7%)
Sep 2013
-
$1.04B(+35.8%)
$3.51B(+141.8%)
Jun 2013
-
$769.00M(-17.9%)
$1.45B(-24.8%)
Mar 2013
-
$937.00M(+22.8%)
$1.93B(-39.7%)
Dec 2012
$3.20B(-58.7%)
$763.00M(-175.1%)
$3.20B(-24.1%)
Sep 2012
-
-$1.02B(-181.4%)
$4.22B(-41.3%)
Jun 2012
-
$1.25B(-43.5%)
$7.19B(-9.8%)
Mar 2012
-
$2.21B(+23.9%)
$7.97B(+2.8%)
Dec 2011
$7.75B(+13.6%)
$1.78B(-8.9%)
$7.75B(+3.6%)
Sep 2011
-
$1.96B(-3.6%)
$7.49B(+1.8%)
Jun 2011
-
$2.03B(+2.0%)
$7.35B(+3.0%)
Mar 2011
-
$1.99B(+31.1%)
$7.14B(+4.6%)
Dec 2010
$6.82B(+5.1%)
$1.52B(-16.7%)
$6.82B(-0.4%)
Sep 2010
-
$1.82B(+0.3%)
$6.85B(+0.4%)
Jun 2010
-
$1.81B(+8.6%)
$6.83B(+1.1%)
Mar 2010
-
$1.67B(+8.2%)
$6.75B(+4.0%)
Dec 2009
$6.49B(+10.0%)
$1.54B(-13.8%)
$6.49B(-4.4%)
Sep 2009
-
$1.79B(+3.0%)
$6.79B(+6.2%)
Jun 2009
-
$1.74B(+23.1%)
$6.39B(+4.1%)
Mar 2009
-
$1.41B(-23.2%)
$6.14B(-1.9%)
Dec 2008
$5.90B(+33.5%)
$1.84B(+31.8%)
$6.26B(+8.6%)
Sep 2008
-
$1.40B(-6.0%)
$5.76B(+5.6%)
Jun 2008
-
$1.49B(-2.8%)
$5.46B(+8.5%)
Mar 2008
-
$1.53B(+13.7%)
$5.03B(+11.8%)
Dec 2007
$4.42B(+33.4%)
$1.35B(+23.5%)
$4.50B(+33.6%)
Sep 2007
-
$1.09B(+2.9%)
$3.37B(+13.6%)
Jun 2007
-
$1.06B(+5.9%)
$2.96B(-6.5%)
Mar 2007
-
$1.00B(+365.6%)
$3.17B(-4.3%)
Dec 2006
$3.31B
$215.00M(-68.8%)
$3.31B(-16.3%)
Sep 2006
-
$688.00M(-45.7%)
$3.96B(-11.4%)
Jun 2006
-
$1.27B(+10.8%)
$4.47B(-1.9%)
DateAnnualQuarterlyTTM
Mar 2006
-
$1.14B(+32.8%)
$4.55B(-2.4%)
Dec 2005
$4.67B(-13.2%)
$861.00M(-28.1%)
$4.67B(-7.8%)
Sep 2005
-
$1.20B(-11.6%)
$5.06B(-4.0%)
Jun 2005
-
$1.35B(+8.0%)
$5.27B(-0.1%)
Mar 2005
-
$1.25B(-0.2%)
$5.28B(-1.7%)
Dec 2004
$5.37B(-6.1%)
$1.26B(-10.9%)
$5.37B(-2.5%)
Sep 2004
-
$1.41B(+3.8%)
$5.51B(-3.1%)
Jun 2004
-
$1.36B(+0.8%)
$5.68B(-1.4%)
Mar 2004
-
$1.35B(-3.2%)
$5.76B(+0.7%)
Dec 2003
$5.72B(+18.3%)
$1.39B(-12.2%)
$5.72B(+10.0%)
Sep 2003
-
$1.59B(+10.4%)
$5.20B(+6.6%)
Jun 2003
-
$1.44B(+9.9%)
$4.88B(+9.0%)
Mar 2003
-
$1.31B(+49.5%)
$4.48B(-7.4%)
Dec 2002
$4.84B(-17.8%)
$874.00M(-30.8%)
$4.84B(-4.7%)
Sep 2002
-
$1.26B(+22.1%)
$5.08B(-7.1%)
Jun 2002
-
$1.03B(-37.9%)
$5.46B(-10.2%)
Mar 2002
-
$1.67B(+49.5%)
$6.08B(-2.1%)
Dec 2001
$5.89B(-12.6%)
$1.11B(-32.4%)
$6.21B(-9.8%)
Sep 2001
-
$1.65B(-0.4%)
$6.89B(-0.9%)
Jun 2001
-
$1.66B(-7.8%)
$6.96B(-0.4%)
Mar 2001
-
$1.79B(+0.2%)
$6.99B(+1.1%)
Dec 2000
$6.73B(+13.8%)
$1.79B(+4.6%)
$6.91B(+3.2%)
Sep 2000
-
$1.71B(+1.7%)
$6.69B(+3.3%)
Jun 2000
-
$1.69B(-1.9%)
$6.48B(+3.2%)
Mar 2000
-
$1.72B(+8.8%)
$6.28B(+1.2%)
Dec 1999
$5.92B(+16.5%)
$1.58B(+5.2%)
$6.20B(+13.9%)
Sep 1999
-
$1.50B(+1.2%)
$5.45B(-0.0%)
Jun 1999
-
$1.48B(-9.8%)
$5.45B(+3.3%)
Mar 1999
-
$1.64B(+99.9%)
$5.28B(+3.9%)
Dec 1998
$5.08B(+1.0%)
$822.00M(-45.3%)
$5.08B(-7.9%)
Sep 1998
-
$1.50B(+14.7%)
$5.52B(+3.1%)
Jun 1998
-
$1.31B(-9.5%)
$5.35B(+2.7%)
Mar 1998
-
$1.45B(+14.9%)
$5.21B(+3.6%)
Dec 1997
$5.03B(+12.5%)
$1.26B(-5.8%)
$5.03B(+3.5%)
Sep 1997
-
$1.34B(+14.5%)
$4.86B(+3.2%)
Jun 1997
-
$1.17B(-7.9%)
$4.71B(+2.6%)
Mar 1997
-
$1.27B(+16.6%)
$4.59B(+2.5%)
Dec 1996
$4.47B(+10.1%)
$1.09B(-8.3%)
$4.47B(+0.8%)
Sep 1996
-
$1.19B(+13.4%)
$4.44B(+3.3%)
Jun 1996
-
$1.05B(-9.3%)
$4.30B(+2.3%)
Mar 1996
-
$1.15B(+9.6%)
$4.20B(+3.3%)
Dec 1995
$4.06B(+14.5%)
$1.05B(+0.7%)
$4.06B(+5.7%)
Sep 1995
-
$1.04B(+10.2%)
$3.85B(+2.4%)
Jun 1995
-
$948.00M(-6.9%)
$3.76B(+2.6%)
Mar 1995
-
$1.02B(+22.1%)
$3.66B(+3.1%)
Dec 1994
$3.55B(+30.9%)
$834.00M(-12.8%)
$3.55B(+22.8%)
Sep 1994
-
$956.00M(+12.2%)
$2.89B(+2.0%)
Jun 1994
-
$852.00M(-6.2%)
$2.83B(+2.5%)
Mar 1994
-
$908.00M(+415.9%)
$2.77B(+2.0%)
Dec 1993
$2.71B(+20.2%)
$176.00M(-80.4%)
$2.71B(+15.5%)
Sep 1993
-
$899.00M(+15.0%)
$2.35B(+0.7%)
Jun 1993
-
$782.00M(-8.4%)
$2.33B(+1.8%)
Mar 1993
-
$854.00M(-554.3%)
$2.29B(+1.5%)
Dec 1992
$2.25B(-25.1%)
-$188.00M(-121.3%)
$2.25B(-26.8%)
Sep 1992
-
$883.00M(+19.3%)
$3.08B(+1.1%)
Jun 1992
-
$740.00M(-9.8%)
$3.05B(-0.2%)
Mar 1992
-
$820.00M(+28.3%)
$3.05B(+1.4%)
Dec 1991
$3.01B(+14.4%)
$639.00M(-24.7%)
$3.01B(+3.6%)
Sep 1991
-
$849.00M(+14.0%)
$2.91B(+2.6%)
Jun 1991
-
$745.00M(-4.4%)
$2.83B(+2.9%)
Mar 1991
-
$779.00M(+45.9%)
$2.75B(+4.6%)
Dec 1990
$2.63B(+105.9%)
$534.00M(-31.2%)
$2.63B(-172.2%)
Sep 1990
-
$776.00M(+16.5%)
-$3.65B(+73.4%)
Jun 1990
-
$666.00M(+1.4%)
-$2.10B(+300.6%)
Mar 1990
-
$657.00M(-111.4%)
-$525.00M(-148.5%)
Dec 1989
$1.28B(-34.6%)
-$5.75B(-347.7%)
$1.08B(-50.4%)
Sep 1989
-
$2.32B(+3.4%)
$2.19B(+6.0%)
Jun 1989
-
$2.24B(-0.9%)
$2.06B(+7.5%)
Mar 1989
-
$2.27B(-148.8%)
$1.92B(+8.4%)
Dec 1988
$1.96B(+20.1%)
-$4.64B(-311.5%)
$1.77B(-20.0%)
Sep 1988
-
$2.20B(+4.5%)
$2.21B(+16.1%)
Jun 1988
-
$2.10B(-0.8%)
$1.91B(+12.5%)
Mar 1988
-
$2.12B(-150.4%)
$1.69B(+15.5%)
Dec 1987
$1.63B
-$4.20B(-322.4%)
$1.47B(-74.1%)
Sep 1987
-
$1.89B(0.0%)
$5.67B(+50.0%)
Jun 1987
-
$1.89B(0.0%)
$3.78B(+100.0%)
Mar 1987
-
$1.89B
$1.89B

FAQ

  • What is Bristol-Myers Squibb annual EBITDA?
  • What is the all time high annual EBITDA for Bristol-Myers Squibb?
  • What is Bristol-Myers Squibb annual EBITDA year-on-year change?
  • What is Bristol-Myers Squibb quarterly EBITDA?
  • What is the all time high quarterly EBITDA for Bristol-Myers Squibb?
  • What is Bristol-Myers Squibb quarterly EBITDA year-on-year change?
  • What is Bristol-Myers Squibb TTM EBITDA?
  • What is the all time high TTM EBITDA for Bristol-Myers Squibb?
  • What is Bristol-Myers Squibb TTM EBITDA year-on-year change?

What is Bristol-Myers Squibb annual EBITDA?

The current annual EBITDA of BMY is $2.44B

What is the all time high annual EBITDA for Bristol-Myers Squibb?

Bristol-Myers Squibb all-time high annual EBITDA is $20.12B

What is Bristol-Myers Squibb annual EBITDA year-on-year change?

Over the past year, BMY annual EBITDA has changed by -$16.93B (-87.40%)

What is Bristol-Myers Squibb quarterly EBITDA?

The current quarterly EBITDA of BMY is $4.48B

What is the all time high quarterly EBITDA for Bristol-Myers Squibb?

Bristol-Myers Squibb all-time high quarterly EBITDA is $5.55B

What is Bristol-Myers Squibb quarterly EBITDA year-on-year change?

Over the past year, BMY quarterly EBITDA has changed by +$13.04B (+152.31%)

What is Bristol-Myers Squibb TTM EBITDA?

The current TTM EBITDA of BMY is $16.20B

What is the all time high TTM EBITDA for Bristol-Myers Squibb?

Bristol-Myers Squibb all-time high TTM EBITDA is $20.12B

What is Bristol-Myers Squibb TTM EBITDA year-on-year change?

Over the past year, BMY TTM EBITDA has changed by +$10.88B (+204.59%)
On this page